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Introduction
The skeleton is a highly dynamic organ that remodels and re-
generates itself in response to biomechanical stress and physio-
logical trauma. Remodeling and regeneration of bone are made 
possible by the coordinated activities of its two specialized cell 
types: osteoblasts, which synthesize and mineralize the bone 
extracellular matrix, and osteoclasts, which secrete hydrolytic 
enzymes that resorb this matrix (Karsenty and Wagner, 2002). 
During embryogenesis and early postnatal development, these 
activities are uncoupled to enable rapid bone matrix production 
and growth in response to high metabolic demand, a process 
termed bone modeling. Accordingly, osteoblasts in prepubertal 
mice demonstrate a remarkable capacity for bone formation 
(Hsiao et al., 2008). Despite significant progress in under-
standing the transcriptional cascades that control skeletogenesis 
(Karsenty, 2008), the posttranscriptional mechanisms that drive 
bone modeling are not well understood.
As the predominant protein synthesized by metabolically 
active osteoblasts, type I collagen accounts for 90% of the 
organic bone matrix (Young, 2003). The production of mature 
type I collagen is a multistep process that is crucial to a bio-
mechanically stable extracellular matrix. A broad spectrum of 
genetically and clinically heterogeneous human skeletal dyspla-
sias are caused by mutations in the two type I collagen chains 
(COL1A1 and COL1A2) or in genes required for collagen pro-
cessing (Byers and Cole, 2002; Morello et al., 2006; Cabral et al., 
2007). Such disorders typically result in low bone mass and 
include the brittle bone disease osteogenesis imperfecta (OI) 
and Ehlers-Danlos syndrome. Unfortunately, few existing ther-
apies to correct disorders of low bone mass target de novo 
bone formation. Thus, it is important to identify new genes 
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uring  skeletal  development  and  regeneration, 
bone-forming osteoblasts respond to high meta-
bolic demand by active expansion of their rough 
endoplasmic reticulum (rER) and increased synthesis of 
type I collagen, the predominant bone matrix protein. 
However, the molecular mechanisms that orchestrate this 
response are not well understood. We show that inser-
tional  mutagenesis  of  the  previously  uncharacterized 
osteopotentia  (Opt)  gene  disrupts  osteoblast  function 
and causes catastrophic defects in postnatal skeletal de-
velopment. Opt encodes a widely expressed rER-localized 
integral membrane protein containing a conserved SUN 
(Sad1/Unc-84 homology) domain. Mice lacking Opt 
develop acute onset skeletal defects that include impaired 
bone formation and spontaneous fractures. These de-
fects result in part from a cell-autonomous failure of   
osteoblast maturation and a posttranscriptional decline in 
type I collagen synthesis, which is concordant with mini-
mal rER expansion. By identifying Opt as a crucial regu-
lator of bone formation in the mouse, our results uncover 
a novel rER-mediated control point in osteoblast function 
and implicate human Opt as a candidate gene for brittle 
bone disorders.
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and molecular networks that regulate osteoblast activity and 
promote bone formation.
The rough ER (rER) plays a central role in the synthesis 
and processing of type I collagen (Lamandé and Bateman, 1999; 
Myllyharju and Kivirikko, 2004). Cotranslational import of 
type I procollagen into the rER is followed by its posttransla-
tional modification (prolyl and lysyl hydroxylation and glyco-
sylation) and chaperone-mediated folding into a triple-helical 
conformation. Regulated secretion and extracellular cleavage of 
the proprotein triple helix then enable its self-assembly into ma-
ture fibrils, which are covalently cross-linked and subsequently 
mineralized to give the bone its characteristic rigidity and tough-
ness. In highly secretory cell types such as osteoblasts and pan-
creatic islet and acinar cells, the rER undergoes active membrane 
expansion, greatly increasing its surface area to meet the meta-
bolic demands of the cell (Vedrenne and Hauri, 2006). Precisely 
how the osteoblast translates the metabolic demand for new bone 
matrix into tightly coordinated rER expansion and increased type I 
collagen production, however, is not clear.
In this study, we identify osteopotentia (Opt), a previously 
uncharacterized rER integral membrane protein, as an essential 
regulator of postnatal osteoblast maturation. Loss of Opt leads 
to impaired type I collagen synthesis and a consequent failure of 
bone modeling. Our results establish a critical role for Opt in 
osteoblastic bone formation and suggest that mutations in human 
Opt may cause OI and other degenerative bone disorders.
Results
Insertional mutagenesis of Opt, a widely 
expressed SUN domain protein
In an insertional mutagenesis screen for genes encoding de-
velopmentally important secreted and transmembrane proteins 
(Mitchell et al., 2001), mutagenesis of the uncharacterized gene 
AI848100 yielded a severe skeletal phenotype; thus, we named 
this gene osteopotentia, or Opt. The Opt locus comprises 24 
exons and encodes a predicted protein of 140 kD, having a 
signal peptide sequence at its N terminus and a single putative 
transmembrane domain near its C terminus (Fig. 1 A). The pro-
tein also contains a highly conserved SUN (Sad1/UNC-84   
homology) domain of 130 residues in the amino-terminal half 
of the protein. SUN domain proteins, including the mammalian 
inner nuclear membrane proteins SUN1 and SUN2, dictate nu-
clear positioning and centromere tethering by physically link-
ing the nucleus and cytoskeleton (Tzur et al., 2006; Ding et al., 
2007; King et al., 2008; Chi et al., 2009; Razafsky and Hodzic, 
2009). No other mouse protein shares extensive sequence simi-
larity with Opt, and genomic database searches identified single 
Opt orthologues in humans, frogs, zebrafish, fruit flies, nema-
todes, and yeast.
Insertion of the gene trap vector into the 1,624-bp 11th 
intron of the Opt locus produces a fusion between the amino-
terminal 424 amino acids of the Opt protein and a transmem-
brane geo reporter (Fig. 1 A). Neither full-length mRNA 
transcripts nor any transcript spanning the insertion site was de-
tected in mice homozygous for the insertion (Fig. 1, B and C). 
Endogenous Opt protein migrated as a doublet of 260 kD, and 
Figure  1.  Identification,  mutagenesis,  and  expression  pattern  of  Opt. 
(A)  Schematic  of  Opt  protein  domain  organization,  showing  the  posi­
tion and orientation of the gene trap insertion (gt; green triangle) and 
RT­PCR primer–binding sites (arrowheads). The positions of the insertion 
and primer sites relative to the protein are shown primarily for illustrative 
purposes and are not drawn precisely to scale. SS, signal sequence; TM, 
putative transmembrane domain; pI, isoelectric point. (B) RT­PCR analysis 
of E13.5 embryos, confirming that Opt transcripts spanning the insertion 
site (blue arrowheads) are not detected in Opt
/ mice. Primers are shown 
as in A. +/+, WT; +/, Opt
+/; /, Opt
/. (C) Widespread Opt ex­
pression demonstrated by Northern blot analysis of tissue samples from 
10­d­old mice and whole E9.5 and E13.5 embryos. Arrows indicate two 
specific transcripts (7.0 and 9.0 kb) that are absent from the E13.5 
Opt
/ sample. 28S, EtBr­stained 28S ribosomal RNA. (D) Immunoblotting   
of E13.5 whole embryo lysates with Opt (top) or ­actin (bottom) anti­
bodies. (E and F) Opt protein expression visualized as ­galactosidase stain­
ing in whole mount (E) and histological sections (F) of newborn calvaria.   
(E) Arrows indicate strong ­galactosidase staining at osteogenic fronts. 
(F) Arrows indicate Opt­expressing osteoblasts lining the bone surface, 
whereas the arrowhead indicates osteocyte expression. Bar, 10 µm.513 Osteopotentia regulates bone formation • Sohaskey et al.
In contrast, most homozygous (Opt
/) mice died neonatally; 
this number was 50% on a mixed C57BL6/CD1 genetic back-
ground and 100% on an inbred C57BL6/129Ola background. 
For this reason, animals on a mixed C57BL6/CD1 background 
were used for all subsequent experiments. Neonatal Opt
/ mice 
frequently showed labored breathing and died after failing to ac-
quire the healthy pink hue of their control littermates; the smaller 
size of the mutant ribcage (Fig. S1) may account for this respira-
tory distress and neonatal lethality. Opt
/ mice that survived 
this perinatal crisis nonetheless failed to thrive and showed sig-
nificantly reduced body weights as early as embryonic day (E) 
18.5 (Fig. 2, A and B). Consistent with normal nutrition, surviv-
ing Opt
/ mice frequently showed a conspicuous milk spot in 
their stomachs and had a normal percentage of body fat as as-
sessed by dual-energy x-ray absorptiometry (unpublished data). 
However, mutant animals displayed an imbalanced gait and an 
impaired righting response, which is suggestive of potential neu-
rological defects. Mortality among surviving Opt
/ mice was 
>80% by postnatal day (P) 10, and none survived to weaning.
Skeletal development was modestly delayed in neonatal 
Opt
/ mice (Fig. 2 C and Fig. S1), with mutant long bones hav-
ing less trabecular and cortical bone than WT (Fig. 2 D). Begin-
ning at P5, Opt
/ mice exhibited striking skeletal deformities 
expression of both bands was negligible in homozygous mutant 
embryos (Fig. 1 D). Importantly, we did not detect smaller mo-
lecular mass bands on Opt immunoblots, indicating that no sta-
ble protein product was synthesized from potential alternatively 
spliced mutant transcripts (Fig. 1 B, purple arrowheads). More-
over, the geo fusion protein is unlikely to retain any Opt activity, 
as “secretory trap” products typically accumulate in cytoplas-
mic inclusion bodies (Skarnes et al., 1995; Mitchell et al., 2001). 
Collectively, these results suggest that the Opt gene trap inser-
tion generates a null or strongly hypomorphic allele.
Opt mRNA and protein are widely expressed during 
embryogenesis and early postnatal life (Fig. 1, C, E, and F). 
-Galactosidase activity was detected in all skeletal elements, 
as demonstrated by whole mount X-gal staining of newborn 
calvaria in which prominent staining was evident at osteogenic 
fronts (Fig. 1 E, arrows). In histological sections, -galactosi-
dase activity was apparent in chondrocytes as well as in osteo-
blasts, osteoclasts, and osteocytes (Fig. 1 F and not depicted).
Mice lacking Opt exhibit catastrophic 
defects in bone modeling
Heterozygous (Opt 
+/) mice were viable, fertile, and pheno-
typically indistinguishable from wild-type (WT) littermates. 
Figure 2.  Growth retardation and low bone 
mass with multiple fractures in Opt 
/ mice. 
(A)  Gross  morphology  of  WT,  Opt 
+/,  and 
Opt 
/ mice at P10. (B) Growth curves for con­
trol (WT and Opt  
+/) and Opt 
/ mice from 
E18.5 to P20. P < 0.0001 for all time points. 
(C) Cleared skeletal preparations of neonatal 
forelimbs stained with Alcian blue for cartilage 
and Alizarin red for bone. Note the delayed 
ossification of metacarpals and phalanges in 
the  Opt 
/  autopod.  The  mutant  forelimb 
was digitally cut and moved within the same 
image using Photoshop to align it with and posi­
tion it in closer proximity to the WT forelimb.   
(D) Longitudinal sections from P0 femurs stained 
with Masson’s trichrome to visualize collagen 
(blue) and muscle (red). Bar, 0.5 mm. (E) µCT 
reconstructions  showing  hyperplastic  fracture 
calluses  (arrows)  at  the  costovertebral  ar­
ticulations of Opt 
/ mice (P20). Bars, 1 mm. 
(F) Longitudinal sections from P10 tibiae (top 
and  middle)  and  calvaria  (bottom)  stained 
with Masson’s trichrome. Bars: (top) 0.5 mm; 
(middle and bottom) 0.1 mm. (G) µCT recon­
structions and bone structural parameters mea­
sured by quantitative µCT (n = 5). *, P < 0.05; 
**, P < 0.01. (H) Polarization microscopy of 
Sirius red–stained collagen fibers, showing ab­
normal birefringence of Opt 
/ cortical bone. 
Bar, 0.1 mm.JCB • VOLUME 189 • NUMBER 3 • 2010   514
Quantitative RT-PCR (qRT-PCR) confirmed a marked reduc-
tion in osteocalcin (Ocn) transcripts in long bone samples from 
P10 Opt
/ mice, along with significant reductions in Alp, Bsp 
(bone sialoprotein), and the prodifferentiation VEGF receptor 
Flk1, as well as Col1a1 and Col1a2, encoding the two type I 
procollagen chains (Fig. 3 B). Importantly, expression of the 
osteoblast-restricted transcription factors Atf4 (activating tran-
scription factor 4), Runx2 (runt-related transcription factor 2), 
and osterix was comparable in WT and Opt
/ samples, sug-
gesting that Opt is dispensable for commitment to the osteo-
blast lineage. These qRT-PCR data were verified by in situ 
hybridization, with Ocn transcripts in particular being nearly 
undetectable in Opt
/ bones (Fig. 3 C). Thus, Opt is crucial 
for postnatal osteoblast maturation. Intriguingly, neither von 
Kossa staining nor osteoblast marker expression was consis-
tently altered in E17.5 mutant femurs (Fig. S2 B). Collectively 
with our finding of delayed ossification in neonatal Opt
/ 
mice (Fig. 2, C and D), these results indicate that Opt is ini-
tially required for proper bone modeling during late embryo-
genesis. Moreover, Opt is dispensable for chondrogenesis, as 
chondrocyte organization and maturation appeared normal in 
E14.5 Opt
/ long bones (Fig. S2 A).
The nominal amount of secondary spongiosa and abnormal 
osteoblast morphology in Opt
/ bones (see Fig. 4 A and Fig. 7 A) 
precluded static histomorphometry of osteoblast parameters. 
Similarly, attempts to quantify bone formation rates after in vivo 
labeling with calcein, a fluorescent indicator of newly formed 
bone, yielded punctate, discontinuous labeling of mutant bone 
surfaces that contrasted sharply with the regular labeling of WT 
surfaces (Fig. 3 D). This is consistent with decreased osteoblast 
marker expression and with the woven appearance of Opt
/ 
bone (Fig. 2 H). Nonetheless, the osteoid that did form through-
out the Opt
/ skeleton appeared properly mineralized (Fig. 3 E), 
suggesting that loss of Opt does not cause rickets.
To address whether decreased proliferation or increased 
cell death contributes to the Opt phenotype, we analyzed corti-
cal bone sections by proliferating cell nuclear antigen (PCNA) 
immunohistochemistry and TUNEL staining. A slight though 
insignificant  increase  in  the  percentage  of  PCNA-positive 
Opt
/ osteoblasts (Fig. 3 F) indicated that reduced cell prolif-
eration is not responsible for the low bone mass. In contrast, 
apoptosis assayed by TUNEL increased from 0.8% in WT bones 
to 1.9% in mutants (Fig. 3 G). Given that apoptotic rates for WT 
mouse osteoblasts in vivo typically fall in the range of 1–2% 
that included misshapen long bones, internal hemorrhaging 
around forelimbs and cervical vertebrae, inflexible joints, and 
spontaneous fractures. Hyperplastic calluses formed throughout 
the Opt
/ axial and appendicular skeleton, which is suggestive 
of aberrant ongoing fracture repair (Fig. 2 E). In addition, 
the cranial vault of Opt
/ mice was flatter than that of control 
littermates, with widened sutures (unpublished data). Histology 
and quantitative microcomputed tomography (µCT) revealed 
significantly reduced trabecular bone volume and dramatically 
thinner cortices in long bones from P10 Opt
/ mice, despite only 
mild perturbations to the organization of growth plate chondro-
cytes (Fig. 2 F). Trabecular number and thickness decreased 
significantly in Opt
/ long bones, whereas trabecular separa-
tion increased (Fig. 2 G). Consistent with these findings, Opt
/ 
cortical bone resembled immature woven bone with sparse and 
randomly oriented type I collagen fibrils, which is in contrast to 
the birefringent, lamellar organization of WT bone (Fig. 2 H). 
Mutant calvarial bones also showed marked thinning (Fig. 2 F), 
confirming that Opt deficiency affects both endochondral and 
intramembranous ossification.
We measured biochemical indices of bone turnover to 
assess whether metabolic abnormalities contribute to the Opt
/ 
brittle bone phenotype (Table I). Serum calcium, phosphate, and 
parathyroid hormone levels were unchanged, whereas a decrease 
in circulating IGF-1 may explain in part the poor growth of Opt
/ 
mice (Baker et al., 1993; Rosen, 2004). Elevated alkaline phos-
phatase (ALP), a condition associated with fracture callus forma-
tion (Glorieux et al., 2000), was also seen in Opt
/ animals. 
Defective ascorbate synthesis has been shown to induce fractures 
in young mice (Mohan et al., 2005); however, serum ascorbate 
levels were normal in the absence of Opt. Moreover, hypoglyce-
mia without hyperinsulinemia (Fig. S4 A) excluded a dysregula-
tion of energy metabolism as the underlying cause of the Opt
/ 
skeletal phenotype. Collectively, these data indicate that Opt defi-
ciency causes a generalized, rapid onset impairment of bone mod-
eling, leading to spontaneous fractures in neonatal mice.
Opt is required postnatally for terminal 
osteoblast differentiation
The  low  bone  mass  and  fracture-prone  nature  of  young 
Opt
/ mice suggested a failure of postnatal osteoblast function. 
Consistent with this hypothesis, serum protein levels of osteo-
calcin, the definitive marker of mature osteoblasts, decreased to 
43% and 18% of controls by P5 and P10, respectively (Fig. 3 A). 
Table I.  Serum parameters in 5-d-old mice
Parameter WT Opt  
+/ Opt 
/ n
Calcium (mg/dl) 4.9 ± 0.5 5.0 ± 0.3 5.2 ± 0.5 10
Phosphate (mg/dl) 16.3 ± 0.4 16.3 ± 0.5 17.4 ± 0.7 10
ALP (U/Iiter) 514 ± 44.7 458 ± 21.9 737 ± 78.3
b 10
IGF­1 (ng/ml) 132 ± 18.3 131 ± 8.48 68.4 ± 11.0
b 9–10
PTH (pg/ml) 49.6 ± 13.2 45.0 ± 6.64 47.6 ± 11.8 13–17
Ascorbic acid (µM) 103 ± 4.22 126 ± 6.39
a 115 ± 5.59 12
PTH, parathyroid hormone. Data are expressed as mean ± SEM.
aP < 0.05.
bP < 0.01.515 Osteopotentia regulates bone formation • Sohaskey et al.
an increase in osteocyte numbers associated with the immature 
woven bone that is prevalent in the Opt
/ skeleton.
To further assess the consequences of Opt inactivation in 
vivo, we analyzed osteoblast maturation during fracture repair 
in postnatal Opt
/ mice. Hyperplastic calluses from P12 (Fig. 4) 
and P15 (not depicted) ribs and long bones consisted largely of 
calcified cartilage associated with Col2a1-expressing chondro-
cytes (Fig. 4, A and C), which is consistent with the reported 
progression of repair in nonstabilized fractures (Thompson 
et al., 2002; Colnot et al., 2003; Behonick et al., 2007). Strikingly, 
small, immature Col1a1-expressing osteoblasts were also evi-
dent throughout the callus and fracture site (Fig. 4, A [insets] 
and D). Time course studies of nonstabilized fracture repair have 
(Jilka et al., 1999), this modest 1% increase in cell death is 
likely a secondary effect of Opt deficiency rather than the pri-
mary cause of the observed defects.
Increased numbers of terminally differentiated osteocytes 
have been reported in association with immature woven bone 
(Noble and Reeve, 2000; Hernandez et al., 2004); thus, we 
quantified osteocyte differentiation markers in WT and Opt
/ 
bones. Consistent with increased osteocyte numbers, expres-
sion of MEPE (matrix extracellular phosphoglycoprotein) was 
significantly up-regulated in Opt
/ calvaria and femurs, whereas 
Dmp1 (dentin matrix protein 1) and Phex (phosphate-regulating 
gene with homologies to endopeptidases on the x chromosome) 
were also up-regulated in mutant calvaria. These data indicate 
Figure 3.  Impaired osteoblast maturation in   
Opt
/  mice.  (A)  Serum  osteocalcin  levels   
expressed as ng/ml (n = 12). (B) qRT­PCR of 
osteoblast markers in femurs from P10 mice   
(n = 4). (C) Radioactive in situ hybridization 
on  serial  sections  from  distal  femurs  (P10). 
Bars, 0.5 mm. (D) Irregular calcein labeling of 
cortical bone surfaces in Opt
/ femurs (P10). 
(D–G) Bars, 0.1 mm. (E) Goldner’s trichrome 
staining of cortical bone in undecalcified femur 
sections  (P10).  Higher  magnification  insets 
of the boxed regions show decreased oste­
oid production (pink) by Opt
/ osteoblasts.   
(F and G) PCNA immunohistochemistry (F) and 
TUNEL analysis (G) of cortical bone from P3 
femurs. Data are expressed as PCNA­positive 
(brown)  or  TUNEL­positive  (green)  cells  per 
total  cell  number  (n  =  5–6  mice/genotype). 
(H  and  I)  qRT­PCR  of  osteocyte  markers  in   
femurs (H) and calvaria (I) from P10 mice.   
*, P < 0.05; **, P < 0.01; ‡, P < 0.0001. 
Error bars indicate SEM.JCB • VOLUME 189 • NUMBER 3 • 2010   516
newly formed bone were undetectable in Opt
/ fractures (Fig. 4, 
B and E). Thus, although a time course study of bone repair in 
spontaneous fractures is precluded, our analysis indicates that 
reported Ocn expression in presumptive perichondrial cells be-
fore the callus remodeling stage (Ferguson et al. 1999; Thompson 
et al. 2002); however, mature Ocn-expressing osteoblasts and 
Figure 4.  Hyperplastic fracture calluses in Opt
/ 
mice lack mature osteoblasts. Images show serial 
sections of three hyperplastic rib calluses (Opt
/) 
or two corresponding intact ribs (WT) from P12 
mice.  (A)  Safranin  O/Fast  green  staining  with 
hematoxylin  counterstain.  Central  fracture  sites 
are indicated by asterisks. Higher magnification 
insets show enlarged active osteoblasts lining the 
WT bone compared with smaller immature osteo­
blasts seen in mutant fracture calluses. Bars: (main 
images)  1  mm;  (insets)  10  µm.  (B)  Polarization 
microscopy of Sirius red–stained collagen fibers, 
showing minimal woven bone formation in Opt
/ 
calluses.  (C–E)  Radioactive  in  situ  hybridization 
for Col2a1 (C), Col1a1 (D), and Ocn (E). Note 
the robust Col1a1 expression but negligible Ocn 
expression in Opt
/ calluses.517 Osteopotentia regulates bone formation • Sohaskey et al.
assessed osteoclast function by qRT-PCR, clinical chemistry, 
and histomorphometric analyses. Expression of several osteo-
clast transcripts, including 3-integrin, calcitonin receptor, ca-
thepsin K, and tartrate-resistant acid phosphatase (TRAP), was 
moderately or significantly reduced in Opt
/ femurs and cal-
varia (Fig. 6, A and B). Likewise, decreased levels of osteoclast-
specific TRAP enzymatic activity were found in the serum and 
long bones of Opt
/ mice (Fig. 6 C), and mutant animals ex-
creted significantly fewer urinary deoxypyridinoline cross-links 
(a specific indicator of bone resorption resulting from type I 
collagen breakdown; Fig. 6 D). Osteoclast numbers were also 
significantly reduced in mutant femurs (Fig. 6 E).
Osteoblasts regulate osteoclastogenesis through the pro-
duction of cytokines, including the proosteoclastogenic factor 
Rankl (receptor activator of nuclear factor-B ligand) and the 
antiosteoclastogenic decoy receptor osteoprotegerin (Opg). The 
Rankl/Opg ratio is a key determinant of the extent of osteoclasto-
genesis (Boyle et al., 2003). In long bones and calvaria from 
Opt
/ mice, the ratio of Rankl to Opg expression was reduced 
by 50% (Fig. 6 F), suggesting that diminished osteoclast func-
tion results at least in part from aberrant osteoblast signaling. 
Collectively with our osteoblast data, these findings indicate 
that Opt deficiency creates a physiological imbalance in which 
decreased bone resorption accompanies a more severe reduc-
tion in bone formation.
Opt promotes the synthesis of type I 
collagen by metabolically active osteoblasts
Our qRT-PCR results revealed comparable Col1a1 and Col1a2 
expression by cultured WT and Opt
/ osteoblasts (Fig. 5 E) 
despite the relatively sparse collagen matrix deposited by mu-
tant osteoblast cultures (Fig. 5 A, middle). This apparent dis-
crepancy suggested that Opt is required for the synthesis and/or 
secretion of type I collagen protein by metabolically active 
osteoblasts. Consistent with impaired protein synthesis, Opt
/ 
osteoblasts were smaller than their WT counterparts in vivo 
(Fig. 7 A). In contrast, bone marrow stromal cells from WT and 
activated osteoblasts at the fracture site robustly express Col1a1 
but fail to express Ocn. Robust Col1a1 expression in turn im-
plies that decreased Col1a1/Col1a2 expression in intact P10 
bones (Fig. 3 B) may result secondarily from the marked dis-
ruption of osteoblast maturation and bone formation in Opt
/ 
mice (see Discussion).
To determine the cellular basis for the skeletal defects in 
Opt
/ mutants, we compared the differentiation capacity and 
bone-forming potential of primary calvarial osteoblasts from WT 
and Opt
/ mice. Consistent with in vivo data, Opt
/ osteoblast 
cultures showed reduced ALP activity, a sparsely formed colla-
gen matrix, and significantly fewer bone nodules than WT cul-
tures after 2 wk in differentiation media (Fig. 5, A and B). These 
defects were not the result of compromised cell matrix adhesion 
and consequent cell death, as WT and mutant osteoblasts adhered 
equally well to a fibronectin or type I collagen substratum (Fig. S3). 
Likewise, BrdU incorporation was similar for WT and Opt
/ 
osteoblasts (Fig. 5 C), again arguing that reduced cell prolifera-
tion does not account for the aberrant differentiation of mutant 
osteoprogenitors. Indeed, when plated at the same density as WT 
osteoblasts, Opt
/ osteoblasts grew at a faster rate, resulting in 
increased cell numbers over a 5-d culture period (Fig. 5 D).
Decreased differentiation potential was confirmed by re-
duced expression of Alp, Bsp, and Ocn in differentiating Opt
/ 
osteoblasts; in contrast, expression of the transcription factors 
Atf4, Runx2, and Osterix remained largely unchanged (Fig. 5 E). 
Thus, like their counterparts in vivo, primary Opt
/ osteoblasts 
differentiated poorly and showed functional defects in type I col-
lagen matrix deposition and bone formation. These findings indi-
cate that the brittle bone phenotype of Opt
/ mice results, at 
least in part, from failed postnatal bone formation secondary to a 
cell-autonomous impairment of osteoblast maturation.
Compromised osteoclast function reveals a 
state of low bone turnover in Opt
/ mice
Because increased bone resorption may exacerbate the low bone 
mass of Opt
/ mice (Karsenty and Wagner, 2002), we next 
Figure  5.  Defective  matrix  deposition  and 
bone formation by Opt
/ osteoblasts. (A) Pri­
mary  calvarial  osteoblasts  were  plated  at 
equal densities and were grown to confluence 
before switching to mineralization media on 
day 0. Cultures were assayed for ALP activity 
or stained with van Gieson reagent (to stain 
collagen  fibrils)  on  day  10,  and  bone  nod­
ules were visualized by Alizarin red staining 
on day 14. (B) Bone formation quantified as 
eluted Alizarin red stain (n = 5 independent 
experiments in triplicate). (C) BrdU incorpora­
tion  by  proliferating  osteoblasts  assayed  on 
day 5 after plating. (D) Growth curves for WT 
and Opt
/ osteoblasts over 5 d (n = 3 inde­
pendent experiments in triplicate). (E) qRT­PCR 
analysis of primary osteoblasts on day 7 of dif­
ferentiation. *, P < 0.05; **, P < 0.01. Error 
bars indicate SEM.JCB • VOLUME 189 • NUMBER 3 • 2010   518
Opt
/ osteoblasts showed a 35–80% reduction in their synthe-
sis of both type I collagen chains, despite a modest (15%) re-
duction in -actin levels (Fig. 7, D and E) and comparable gene 
expression of Col1a1 and Col1a2 (Fig. 7 F). Delayed electro-
phoretic migration of collagen chains from mutant cells sug-
gested their overmodification (Fig. 7, D and G); however, no 
change in hydroxylation (prolyl 3, prolyl 4, or lysyl) was de-
tected by tandem mass spectrometry (not depicted). Importantly, 
decreased collagen levels were not caused by impaired secre-
tion and intracellular retention of procollagen, as type I procol-
lagen  assessed  by  immunoblotting  was  similarly  reduced  in 
Opt
/ osteoblast lysates (Fig. 7 D, Pro-1(I)) as well as in 
mutant long bones and calvaria (not depicted). In addition, 
steady-state expression of the ER-resident proteins GRP78/BiP, 
GRP94,  and  calnexin  was  unchanged  in  mutant  osteoblasts   
(Fig. 7 H), indicating that the decreased synthesis seen for type I 
collagen did not broadly affect secretory pathway proteins.
To further establish whether loss of Opt causes a general-
ized defect in protein synthesis, we examined the pancreas, an-
other organ adapted to robust protein synthesis and secretion. 
Neither endocrine nor exocrine pancreatic function or ultrastruc-
ture was altered by Opt deficiency (Fig. S4), as mutant acini con-
tained abundant zymogen granules and extensive rER surface 
area, unlike the sparse rER of mutant osteoblasts. Moreover, 
Opt
/ mice were similar in size, again suggesting that Opt de-
ficiency is particularly detrimental to committed osteoblasts. 
Ultrastructural analyses also supported a defect in protein 
synthesis in mutant osteoblasts. Strikingly, although WT osteo-
blasts demonstrated the extensive, well-organized rER charac-
teristic of metabolically active cells, Opt
/ osteoblasts adopted 
a fibroblastic appearance with a scarce, discontinuous rER net-
work and a higher nuclear/cytoplasmic ratio (Fig. 7 B). Consis-
tent with the modest delay in bone formation seen in neonatal 
mice (Fig. 2, C and D), similar though less-pronounced ultra-
structural  defects  were  observed  in  osteoblasts  from  E17.5 
Opt
/ long bones (Fig. S2 C).
To directly test the hypothesis that Opt is crucial for type I 
collagen synthesis in mature osteoblasts, we metabolically la-
beled proliferating (5 d after plating) and confluent differentiat-
ing (12 d after plating) osteoblast cultures for 12 h in media 
containing nonessential amino acids and quantified the result-
ing radiolabeled collagen (Fig. 7 C). When normalized to -actin 
protein levels, no significant difference was measured in the 
amount of type I collagen synthesized by proliferating WT and 
Opt
/ osteoblasts (Fig. 7 E). Notably, absolute levels of both 
type  I  collagen  and  -actin  were  increased  in  proliferating 
Opt
/ cultures (Fig. 7 D), which is consistent with the faster 
growth rate of mutant cells (Fig. 5 D). In contrast, differentiating 
Figure  6.  Opt
/  mice  exhibit  diminished 
osteoclast function. (A and B) qRT­PCR of osteo­
clast markers in femurs (A; n = 4) and calvaria 
(B;  n  =  5)  from  P10  mice.  (C)  Decreased   
osteoclast­specific TRAP activity in Opt
/ bones 
assayed by histochemical staining (P10 tibial 
sections)  and  serum  ELISA  (P5  mice).  Bars, 
0.1 mm. (D) Urinary deoxypyridinoline (DPD) 
cross­links from P5 mice (n = 9–10). (E) Osteo­
clast  number/bone  surface  (N.Oc/BS)  and 
osteoclast surface/bone surface (OcS/BS) in 
femurs  from  P10  mice  (n  =  5).  (F)  Reduced 
ratio of Rankl to Opg expression in Opt
/ 
femurs  and  calvaria  assessed  by  qRT­PCR.   
*, P < 0.05; **, P < 0.001.519 Osteopotentia regulates bone formation • Sohaskey et al.
Discussion
The molecular mechanisms underlying the osteoblastic response 
to high metabolic demand during perinatal bone modeling are 
not well understood. In this study, we report that Opt, a newly 
identified integral membrane protein of the rER, plays an essen-
tial role in promoting type I collagen synthesis, rER expansion, 
and terminal osteoblast differentiation. Our results implicate 
Opt as a crucial determinant of bone mass in mice and suggest 
that its inactivation may likewise lead to metabolic bone disease 
in humans.
The most conspicuous feature of the Opt
/ phenotype 
was its acute onset, progressing from a developmentally delayed 
but intact skeleton at birth to severely impaired bone formation 
and widespread fractures by P10. Coincident with skeletal de-
generation, we uncovered an abrupt failure of osteoblast matu-
ration in vivo as indicated by a rapid decline in serum osteocalcin 
and bone Ocn expression. Similarly, type I collagen synthesis 
in  cultured  Opt
/  osteoblasts  dropped  significantly  during   
the transition from a proliferative to a differentiating state. In 
contrast, osteocyte gene expression was up-regulated in mutant 
bones, suggesting that immature osteoblasts lacking Opt may 
bypass the normal differentiation program and instead undergo 
premature terminal differentiation to less metabolically active 
osteocytes. Loss of Opt did not alter the expression of transcrip-
tion factors that drive commitment to the osteoblast lineage, 
which is consistent with a requirement for Opt in the matura-
tion of committed osteoblasts. A second notable feature of the 
Opt
/ phenotype was the restriction of overt consequences of 
Opt deficiency to endochondral and membranous bone. This ap-
parent specificity may reflect the importance of Opt for type I 
collagen synthesis, as type I collagen is the major protein syn-
thesized by osteoblasts and constitutes 90% of the organic 
bone matrix (Young, 2003). In this respect, our finding that pri-
mary differentiating Opt
/ osteoblasts synthesize and secrete 
reduced amounts of overmodified collagen chains supports the 
conclusion that Opt in osteoblasts is essential for proper type I 
collagen synthesis and/or processing. Compromised collagen 
synthesis in turn may explain the acute onset of low bone mass 
and fractures in perinatal Opt
/ mice undergoing robust bone 
formation and rapid growth.
Consistent  with  in  vivo  results,  cultured  Opt
/  osteo-
blasts synthesized a sparse collagen matrix and formed less-
mineralized bone than WT osteoblasts. However, unlike the 
situation in vivo, Col1a1 and Col1a2 mRNA expression was 
not significantly decreased in primary osteoblasts from mutant 
mice. Together with the smaller size of Opt
/ osteoblasts in vivo, 
these data suggested a posttranscriptional defect in type I colla-
gen synthesis that was confirmed by metabolic labeling. Based 
on these results, we hypothesize that during late embryonic and 
early postnatal development, suboptimal synthesis of poten-
tially overmodified type I collagen by Opt
/ osteoblasts, coupled 
with ongoing osteoclastic resorption, produces an inadequate 
matrix that limits osteoblast differentiation, as reflected by de-
creased expression of osteoblast marker genes, including Col1a1/
Col1a2 and Ocn (Fig. 9; Aronow et al., 1990; Andrianarivo et al., 
1992; Lynch et al., 1995). Impaired osteoblast differentiation 
aside from modest glomerular hypercellularity in the kidneys, 
no gross histological changes were detected in other major or-
gans from Opt
/ mice (unpublished data). These data suggest 
that Opt is dispensable for normal pancreatic function in young 
mice and argue that, despite its widespread expression, impaired 
protein synthesis is not an inevitable consequence of Opt defi-
ciency in nonskeletal tissues. In contrast, the metabolic demands 
of perinatal bone formation reveal that Opt is a critical regulator 
of type I collagen synthesis in osteoblasts.
Opt is a glycosylated transmembrane 
protein of the rER
Based on the disrupted ER ultrastructure and decreased type I 
collagen synthesis in Opt
/ osteoblasts, we tested the hypothesis 
that Opt encodes an ER-localized protein. When overexpressed 
in primary osteoblasts or established cell lines, epitope-tagged 
full-length Opt showed extensive colocalization with the general 
ER markers calnexin and protein disulfide isomerase but limited 
colocalization with the Golgi markers TGN46 and GM130 
(Fig. 8 A and not depicted). ER localization was not disrupted by 
deletion of the SUN domain (Fig. 8 A, bottom) or by treatment 
with brefeldin A, a fungal metabolite that causes Golgi disassem-
bly (unpublished data). Our attempts to detect endogenous Opt 
by indirect immunofluorescence were unsuccessful; thus, we frac-
tionated WT mouse embryonic fibroblast lysates by continuous 
density gradient ultracentrifugation and analyzed fractions by 
immunoblotting. Endogenous Opt cofractionated with ER mark-
ers but showed no overlap with markers of the Golgi or plasma 
membrane (Fig. 8 B). Notably, Opt fractionated most precisely 
with ribophorin I, a ribosomal binding protein that localizes spe-
cifically to the rER (Kreibich et al., 1978).
N-glycosylation status can also be used to track a protein’s 
position in the secretory pathway, and Opt contains 11 potential 
N-glycosylation sites in its predicted luminal domain. Before 
transiting from the ER to the Golgi, N-linked carbohydrates are 
sensitive to hydrolysis by the glycosidase Endo H; subsequently, 
they become resistant to Endo H while gaining sensitivity to the 
glycosidase PNGase F. Like the well-characterized ER luminal 
protein GRP94, Opt demonstrated sensitivity to both Endo H 
and PNGase F (Fig. 8 C). In contrast, the Golgi-resident protein 
JAWS/gPAPP (Frederick et al., 2008; Sohaskey et al., 2008) 
showed sensitivity to PNGase F but not Endo H. We conclude 
that Opt is an N-glycosylated rER-resident protein.
Fractionating lysates into membrane and cytosolic com-
partments revealed that Opt, like the ER integral membrane pro-
tein calnexin, partitions exclusively into the membrane fraction 
(Fig. 8 D). Treatment of membranes with high salt or alkaline 
pH failed to release Opt into the soluble fraction, whereas 
treatment with detergent solubilized most of the membrane-
associated calnexin but only a limited portion of the Opt (Fig. 8 E). 
Moreover, Opt partitioned into the detergent phase during   
Triton X-114 phase separation (unpublished data), confirming 
its membrane localization and excluding the possibility that the 
protein is sequestered in the ER lumen. Collectively, these find-
ings identify Opt as a glycosylated integral membrane protein 
of the rER, with its amino-terminal SUN domain exposed to the 
rER lumen (Fig. 8 F).JCB • VOLUME 189 • NUMBER 3 • 2010   520
Figure 7.  Opt is essential for type I collagen synthesis in differentiating osteoblasts. (A) Masson’s trichrome staining of P10 tibial sections. Arrows indicate 
osteoblasts lining the endosteal bone surface (left), and WT osteoblasts are delineated by the dashed lines. Opt
/ osteoblasts are considerably smaller, 
whereas bone marrow stromal cells (BMSCs; right) are similar in size to WT. Bar, 10 µm. (B) Transmission electron microscopy of osteoblasts in P10 tibiae. 
(bottom) Higher magnification views of boxed regions show extensive, well­organized rER cisternae in WT that are absent in the more fibroblast­like Opt
/ 
cell. Bars: (top) 1 µm; (bottom) 0.5 µm. (C) Schematic timeline for metabolic labeling of osteoblasts. (D) 7% SDS­PAGE analysis of type I collagen synthesis 
by [
3H]proline­labeled proliferating and differentiating osteoblast cultures (top). Radiolabeled collagen from the media fraction is shown, with loading 521 Osteopotentia regulates bone formation • Sohaskey et al.
long bones subjected to load-bearing stresses provides a com-
pelling explanation for the increased incidence of spontaneous 
fractures throughout the Opt
/ appendicular and axial skeleton.
The disruption of rER ultrastructure in vivo and the pro-
duction of overmodified collagen chains ex vivo suggested that 
the rER is defective in osteoblasts lacking Opt, an rER integral 
membrane protein. Specifically, decreased production of over-
modified collagen by Opt
/ osteoblasts implies that Opt may 
be an essential component of the osteoblast protein synthesis 
and processing machinery that couples robust collagen synthe-
sis to maximal rER expansion. In this regard, a recent quantita-
tive screen in Saccharomyces cerevisiae for gene deletions that 
disrupt ER protein folding identified Slp1, the budding yeast 
orthologue of Opt (Jonikas et al. 2009); however, a precise 
biochemical function for Slp1 remains elusive. Alternatively, 
given that the ER and outer nuclear membrane form a contigu-
ous network, Opt may ensure rER integrity through binding of 
its SUN domain to one or more unidentified KASH domain 
proteins in the nuclear or rER membrane (Tzur et al., 2006; 
Ding et al., 2007; King et al., 2008; Chi et al., 2009; Razafsky 
and Hodzic, 2009). In this way, Opt may ensure rER membrane 
integrity and thus responsiveness to increased metabolic de-
mand, a hypothesis supported by our ultrastructural analyses 
showing a sparsely organized rER in Opt
/ osteoblasts. Loss 
would then exacerbate the skeletal phenotype by further dimin-
ishing collagen synthesis and matrix deposition, culminating in 
brittle bones. The discrepancy between our in vivo and ex vivo 
Col1a1/Col1a2 expression data remains to be resolved but may 
reflect complex regulatory mechanisms that are uncoupled in 
primary Opt
/ cultures (Lian and Stein, 1992). For example, 
mature osteoblasts can influence the differentiation potential 
of immature osteoblasts in vivo (Wang et al., 2007; Mak et al., 
2008), raising the possibility that the acute loss of mature osteo-
blasts in Opt
/ mice secondarily impairs the differentiation of 
immature  Col1a1/Col1a2-expressing  cells.  Supporting  this 
model (Fig. 9), analyses of fracture calluses in Opt
/ mice re-
vealed robust Col1a1 expression in the absence of Ocn expres-
sion and appreciable bone formation, suggesting that decreased 
Col1a1/Col1a2 expression in intact P10 bones is a secondary 
consequence of reduced matrix deposition.
Our data do not exclude that Opt may have other cell-
autonomous roles unrelated to collagen production during 
osteoblast  maturation  or  that  additional  noncell-autonomous 
mechanisms may contribute to the skeletal defects of Opt
/ 
mice. Consistent with these possibilities, plating primary Opt
/ 
osteoblasts on type I collagen failed to restore WT bone forma-
tion (Fig. S3 B). Nonetheless, the combined effect of reducing 
collagen  translation  and  ultimately  transcription  in  postnatal 
normalized by sample volume rather than cell number. ­Actin and intracellular procollagen levels were assessed by immunoblotting, whereas van Gieson 
staining (bottom) confirms the sparse collagen matrix deposited by Opt
/ osteoblasts. (E) Quantification of type I collagen synthesis (1 and 2 chains) 
by proliferating and differentiating osteoblasts normalized to ­actin control (n = 4 independent experiments in triplicate). *, P < 0.02. (F) qRT­PCR analysis 
of Col1a1 and Col1a2 expression in differentiating osteoblasts. (G) Overmodification of radiolabeled 1(I) and 2(I) collagen chains from differentiating 
Opt
/ osteoblasts, as indicated by their delayed electrophoretic migration. The autoradiogram shows radiolabeled collagen from the cellular fraction of 
duplicate cultures and represents an independent experiment from that shown in D. (H) Immunoblotting for the ER chaperones GRP78/BiP, GRP94, and 
calnexin in whole cell lysates of metabolically labeled, primary differentiating osteoblasts. ­Actin serves as a loading control. Results from two independent 
experiments are shown. Error bars indicate SEM.
 
Figure 8.  Opt is a glycosylated integral mem-
brane protein of the rER. (A) Indirect immuno­
fluorescence of HA­tagged full­length (FL) and 
SUN  domain–deleted  (SUN)  Opt  in  trans­
fected primary osteoblasts. Antibodies against 
calnexin  and  TGN46  were  used  to  label 
the ER and Golgi, respectively. Bar, 10 µm.   
(B)  Subcellular  fractionation  of  mouse  em­
bryonic  fibroblast  lysate  on  a  continuous   
(0–20%)  iodixanol  density  gradient.  10  frac­
tions  were  collected  and  analyzed  by  SDS­
PAGE  and  immunoblotting.  Ribophorin  I, 
GM130,  and  Na
+/K
+  ATPase­1  mark  the 
rER, Golgi, and plasma  membrane,  respec­
tively. (C) Opt is N­glycosylated. Denatured 
lysate was treated with buffer () or with the 
N­glycosidases PNGase F or Endo H (+), and 
samples were immunoblotted for Opt, the Endo 
H–sensitive  ER  glycoprotein  GRP94,  or  the 
Endo  H–resistant  Golgi  glycoprotein  JAWS/
gPAPP. (D) Cytosolic and membrane fractions 
were immunoblotted for the indicated proteins. 
(E) Membrane fractions were treated with buf­
fer ± 1 M NaCl, 0.1 M Na2CO3, pH 11, or 
1% Triton X­100 and recentrifuged. The re­
sulting membrane (M) and soluble (S) fractions 
were immunoblotted for Opt or calnexin, an ER­
integral membrane protein. (F) Diagram show­
ing the proposed orientation of Opt in the rER 
membrane, with the SUN domain on the lume­
nal side. Black circles represent ribosomes.JCB • VOLUME 189 • NUMBER 3 • 2010   522
phenotype and OI type V (Glorieux et al., 2000). Although mu-
tations in the genes encoding the collagen-modifying proteins, 
cartilage-associated protein and prolyl 3-hydroxylase 1, have 
been identified in several patients (Morello et al., 2006; Cabral 
et al., 2007), the genetic etiology of other diverse subtypes 
including OI type V is not known. We speculate that loss of 
function mutations in human Opt may underlie one or more 
noncollagen OI subtypes, although initial experiments to test 
this hypothesis identified no significant change in Opt transcript 
or protein levels in fibroblasts from four OI type V probands. 
Likewise, mutations in Opt may contribute to fibrogenesis 
imperfecta ossium, a rare bone disorder of unknown etiology, 
which, like the Opt phenotype, manifests with fractures, abnor-
mal collagen birefringence, and elevated serum ALP (Baker, 
1956; Sissons, 2000). Finally, several major quantitative trait 
loci for bone mineral density map to the region of chromosome 1 
containing the Opt locus (Xiong et al., 2009). Thus, our data 
implicate human Opt as a novel candidate gene for OI and other 
disorders of low bone mass. Further study of how Opt influ-
ences ER dynamics and promotes type I collagen synthesis will 
be instrumental in better understanding the brittle bone pheno-
type that results from Opt deficiency.
of rER integrity in turn may reduce the efficiency of collagen 
synthesis and processing, leading to the decreased synthesis 
of overmodified collagen. Together with these possibilities and 
analogous to nuclear membrane–localized SUN domain pro-
teins, Opt may act as a biomechanical adaptor protein that 
connects the rER lumen to the cytoskeleton, positioning and 
stabilizing the rER within the cell and enabling communication 
between distinct intracellular environments. The relative resis-
tance of membrane-bound Opt to detergent solubilization is 
consistent with such an association. These possibilities are not 
mutually exclusive but provide testable hypotheses for how the 
metabolically active osteoblast couples type I collagen synthe-
sis to rER expansion.
The  short  stature  and  skeletal  defects  of  Opt
/  mice 
strongly resemble those of patients having severe or lethal forms 
of OI. Classical OI is caused by mutations in either of the two 
genes encoding type I collagen (Byers and Cole, 2002); how-
ever,  a  spectrum  of  distinct  clinical  subtypes  not  linked  to 
Col1a1 or Col1a2 has also been reported (Aitchison et al., 1988; 
Williams et al., 1989; Wallis et al., 1993; Glorieux et al., 2002; 
Ward et al., 2002). In particular, hyperplastic callus formation 
and abnormal bone lamellation are hallmarks of both the Opt
/ 
Figure 9.  Model for the Opt-dependent con-
trol of osteoblast function and bone formation. 
Opt at the rER membrane promotes bone for­
mation  by  enabling  maximal  rER  expansion 
and robust type I collagen synthesis. Collagen 
matrix deposition in turn potentiates osteoblast 
maturation,  leading  to  bone  mass  accrual. 
Black circles represent ribosomes.523 Osteopotentia regulates bone formation • Sohaskey et al.
were pooled, plated at 12,000 cells/cm
2 in 6­well plates, grown to conflu­
ence in MEM/10% FBS with antibiotics, and differentiated in media con­
taining 100 µg/ml ascorbate and 5 mM ­glycerophosphate. For the 
experiments shown in Fig. S3, osteoblasts were plated in collagen I 6­well 
multiwell plates (BD). For histochemical assessment of ALP activity, osteo­
blast cultures were fixed in 4% paraformaldehyde and stained for 20 min 
with a solution containing 0.1 mg/ml naphthol AS­MX phosphate and 
0.6 mg/ml Fast blue BB salt (Sigma­Aldrich). To visualize the collagen matrix, 
cell cultures were fixed in 4% paraformaldehyde, stained for 10 min with 
van Gieson reagent (prepared as 10 ml 1% acid fuchsin in 100 ml satu­
rated aqueous picric acid), rinsed twice with 70% ethanol, and dehydrated 
to 100% ethanol.
For mineralization assays, cultures were fixed in 4% paraformalde­
hyde, stained for 30 min with 0.1% Alizarin red, pH 5.5, and rinsed sev­
eral times with deionized water to remove nonspecifically bound stain. The 
retained Alizarin red was eluted with 10% cetylpyridinium chloride and 
quantified spectrophotometrically at 562 nm relative to known calcium 
standards. ALP­, van Gieson–, and Alizarin red–stained osteoblast cultures 
were imaged on a flatbed scanner (Perfection 2450; Epson). For determi­
nation of cell number, cultures were fixed in 4% paraformaldehyde, per­
meabilized with 20% methanol, stained for 30 min with 0.5% crystal violet 
(Sigma­Aldrich) in 20% methanol, and rinsed three times with deionized 
water to remove nonspecifically bound stain. The retained crystal violet 
was eluted with 10% acetic acid and quantified spectrophotometrically at 
595 nm. Cell proliferation in primary osteoblasts was measured by a BrdU 
cell proliferation assay (EMD). Collagen synthesis was assessed by meta­
bolic labeling as described previously (Yang et al., 2004; Yu et al., 2005). 
In brief, proliferating or differentiating osteoblasts were labeled for 12 h 
with 50 µCi/ml [
3H]proline (GE Healthcare) in MEM supplemented with 
2% dialyzed FBS and 2 mM GlutaMAX (Invitrogen). Osteoblasts were har­
vested  by  scraping  into  500  µl  ice­cold  PBS  with  protease  inhibitors 
(Roche), and a 200­µl fraction was reserved for ­actin and procollagen­
1(I) immunoblotting. Procollagen from the medium and cell layers was di­
gested to collagen with 50 µg/ml pepsin in 0.5 M acetic acid for 24 h at 
4°C, precipitated with 0.7 M NaCl, and resolved by SDS­PAGE on a 7% 
gel containing 2 M urea. Gels were impregnated with fluorographic re­
agent (Amplify; GE Healthcare), dried, and exposed to BioMax MS film 
(Kodak). Type I collagen signal intensity was quantified using the ImageJ 
software (version1.40g; National Institutes of Health) and normalized to 
­actin protein expression.
Transmission electron microscopy and confocal imaging
After initial fixation by intracardial perfusion, dissected tibiae and pan­
creas were fixed at 4°C in 2% paraformaldehyde/2% glutaraldehyde/0.1 M 
sodium cacodylate, pH 7.35. To decalcify tibiae from P10 mice, 0.1 M 
EDTA was included in the fixative, and samples were nutated gently for 
10–14 d at 4°C. Samples were washed to remove excess EDTA, postfixed 
in 1% osmium tetroxide, dehydrated, and embedded in epon (epoxy) resin 
(Hayat, 2000). Ultrathin sections of 80 nm were stained with uranyl ace­
tate and viewed with a transmission electron microscope (Philips CM120; 
FEI Company), and images were captured with a digital camera (BioScan; 
Gatan). Osteoblasts were identified by their morphology and proximity to 
the bone matrix. For indirect immunofluorescence, cells grown on 24­well 
glass coverslips were transfected with 250 ng OptFL or OptSUN using 
Lipofectamine 2000 reagent (Invitrogen), fixed and permeabilized in methanol/
acetone 40–48 h later, blocked in 5% goat serum, immunostained with 
primary antibodies overnight, and visualized with Alexa Fluor 488– and 
555–conjugated  secondary  antibodies  (Invitrogen).  Coverslips  were 
mounted in mounting medium (Vectashield HardSet; Vector Laboratories) 
and stored in the dark at 4°C. Confocal imaging was performed with a   
microscope (DM RE; Leica) using a 63× 1.4 NA oil immersion objective 
lens and TCS software (version 2.61; Leica). Images were processed for 
brightness and contrast using Photoshop (version 7.0).
Subcellular fractionation
Membrane and cytosolic fractions were prepared by a standard ultracen­
trifugation protocol. For subcellular fractionation, mouse embryonic fibro­
blasts (5 × 10
7) were resuspended in ice­cold homogenization buffer 
(0.25 M sucrose in 10 mM Hepes, pH 7.4, and 1 mM EDTA) and dis­
rupted gently by 30 strokes in a prechilled Wheaton dounce homogenizer 
followed by five passages through a 22­gauge needle. After a 10­min cen­
trifugation step at 2,000 g, the postnuclear supernatant was layered atop 
a continuous 0–20% iodixanol (OptiPrep; Sigma­Aldrich) density gradi­
ent prepared in homogenization buffer. Gradients were centrifuged at 
34,100 rpm for 3.25 h at 4°C in a rotor (SW41Ti; Beckman Coulter), and 
10 fractions were collected from the top of the tube. Gradient integrity was 
Materials and methods
Mouse strains
The KST50 mouse embryonic stem cell line, containing an insertion of the 
pGT0TMpf gene trap vector in the Opt locus, was isolated and character­
ized as described previously (Mitchell et al., 2001). Opt F1 heterozygotes 
were backcrossed to C57BL/6 mice for at least six generations before inter­
crossing. Genotyping was performed by X­gal staining of yolk sacs and/or 
tail  biopsies  or  by  RT­PCR  using  primers  flanking  the  insertion  site   
(forward,  5­TTCTAATGGAGGTCCACATGC­3;  Opt­specific  reverse,   
5­TGACGTTCTGACTGATACTGGG­3; gene trap vector–specific reverse, 
5­GAGACCTGGGGTATCTGAAGG­3). All animal experiments were ap­
proved by the University of California Berkeley Institutional Animal Care 
and Use Committee.
Morphological analysis, histology, and in situ hybridization
Alcian blue and Alizarin red staining of skeletal preparations, X­gal stain­
ing, and radioactive in situ hybridization with 
35S­labeled riboprobes were 
performed according to established protocols (Nagy, 2003). To assess 3D 
trabecular and 2D cortical structural parameters, the distal femur and prox­
imal tibia from 10­d­old mice were measured directly as described previ­
ously (Jiang et al., 2005) using a desktop µCT 40 with an isotropic 
resolution of 12 µm in all three spatial dimensions (SCANCO Medical). 
For histological analysis of collagen matrix, deparaffinized 6­µm sections 
were stained by Masson’s trichrome and counterstained with Weigert’s 
iron  hematoxylin  (Sigma­Aldrich).  Alternatively,  collagen  fibers  were 
stained with Sirius red F3B/Direct red 80 (Sigma­Aldrich) for polarization 
microscopy. Undecalcified sections from methylmethacrylate­embedded 
femurs were stained by Goldner’s trichrome to distinguish osteoid from min­
eralized bone. Fracture calluses were visualized by staining with 0.02% 
aqueous Fast green (Sigma­Aldrich) followed by rinsing in 1% acetic acid 
and staining in 0.1% Safranin O (Sigma­Aldrich). Cell proliferation and 
apoptosis were quantified in deparaffinized 6­µm serial sections of P3 
hindlimbs using a PCNA staining kit (Invitrogen) and In situ Cell Death   
Detection kit (Roche), respectively. TRAP activity was visualized histochemi­
cally using the Leukocyte Acid Phosphatase kit (Sigma­Aldrich). Sections 
were viewed with a microscope (Axioplan; Carl Zeiss, Inc.) equipped with 
Plan Neofluar objectives (10× 0.3 NA, 20× 0.5 NA, and 40× 0.75 NA) 
and Chroma optical filters (41001 FITC, 41004 Texas red, and 31000 
DAPI/Hoechst),  and  images  were  captured  using  a  digital  camera 
(DFC500; Leica). To enhance contrast against the Hoechst counterstain,   
radioactive in situ signals were photographed in brightfield and pseudo­
colored red using the Colorize option within the Hue/Saturation command 
in Photoshop (version 7.0; Adobe).
Bioinformatics, antibodies, and expression experiments
Opt transcripts were detected by Northern blotting of TRIzol­extracted total 
RNA  probed  with  a 
32P­labeled  cDNA  fragment  spanning  nucleotides 
4,399–5,120  of  the  Opt  mRNA  (Mouse  Genome  Informatics  no. 
AI848100; GenBank accession no. NM_172645.2). Alternatively, total 
RNA was purified using the RNeasy MinElute Cleanup kit (QIAGEN), and 
mRNA expression was assessed by qRT­PCR with SYBR green reagents on 
a system (7300; Applied Biosystems) using ­tubulin as an internal refer­
ence. Primer sequences are provided in Table S1. For heterologous expres­
sion, the full­length Opt open reading frame (OptFL) was PCR amplified 
from WT femur cDNA and subcloned into a modified pcDNA3 vector   
(Invitrogen) containing a C­terminal HA epitope tag. An Opt fragment lacking 
the SUN domain was generated by overlap PCR and substituted for the 
BstXI–EcoRI fragment of OptFL to generate the OptSUN construct. All 
constructs were verified by sequencing. For Opt immunoblotting, a rabbit 
polyclonal antibody was raised and affinity purified against the peptide 
N­CQKTKTEKRALKRRRSK­C corresponding to an epitope in the Opt cytosolic 
domain (Covance). Other primary antibodies were rabbit type I collagen 
(AB765P; Millipore), rabbit actin C­11 (Santa Cruz Biotechnology, Inc.), 
mouse HA tag HA­7 (Sigma­Aldrich), rabbit calnexin (C4731; Sigma­
Aldrich), rabbit Erk2 C­14 (Santa Cruz Biotechnology, Inc.), mouse GM130 
(BD), and mouse Na
+/K
+ ATPase ­1 C464.6 (Millipore).
Primary cell cultures and metabolic labeling
Mouse embryonic fibroblasts were isolated from E13.5 embryos accord­
ing to established protocols, maintained in high glucose DME (Invitrogen) 
with 10% FBS (HyClone) and antibiotics, and used after no more than five 
passages. Primary calvarial osteoblasts were isolated from 4­ to 8­d­old 
mice by five sequential digestions in PBS containing 0.1% collagenase P 
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confirmed using an Abbe refractometer. Proteins were precipitated in 
10% trichloroacetic acid, washed with ice­cold acetone, and analyzed by 
SDS­PAGE and immunoblotting using Western Lightning Plus­ECL substrate 
(PerkinElmer) for signal detection. Similar results were obtained by dis­
continuous sucrose density gradient ultracentrifugation.
Clinical biochemistry
Serum and urine parameters were quantified by ELISA using commercially 
available kits for mouse osteocalcin (Biomedical Technologies), IGF­1 
(Diagnostic Systems Laboratories), parathyroid hormone (Immutopics), osteo­
clast­specific TRAP 5b (Immunodiagnostic Systems), insulin (Crystal Chem), 
and total urinary deoxypyridinoline (Quidel). Ascorbic acid (BioVision) 
and urinary creatinine (Quidel) were quantified by colorimetric assay. Cal­
cium, phosphate, ALP, and glucose were measured by the Comparative 
Pathology Laboratory at the University of California (Davis, Davis, CA).
Statistical analysis
Data are expressed as mean ± SEM. Student’s t test and analysis of vari­
ance with Tukey’s Honestly Significant Difference post hoc test were used 
to calculate statistical significance for two and three samples, respectively. 
Statistical analysis was performed using Kaleidagraph (version 4.0; Syn­
ergy Software), and values were considered significant at P < 0.05.
Online supplemental material
Fig. S1 shows developmentally delayed but intact skeletal elements from 
newborn Opt
/ mice. Fig. S2 shows chondrocyte and osteoblast differen­
tiation markers in E14.5 and E17.5 embryos, respectively, and representa­
tive transmission electron microscopy images of osteoblasts from E17.5 
embryos. Fig. S3 shows that plating Opt
/ osteoblasts on type I collagen 
neither normalizes bone formation nor reveals any defects in cell matrix 
adhesion. Fig. S4 shows that Opt deficiency does not affect pancreatic 
function or morphology. Table S1 provides sequences for qRT­PCR primers 
used in this study. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.201003006/DC1.
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